The National Comprehensive Cancer Network (NCCN) guidelines (version 1.2021) recommend genetic evaluation, including the genes BRCA1, BRCA2, TP53, ATM, CDH1, CHEK2, NBN, NF1, and PALB2 for high-risk breast and/or ovarian cancer patients [18]. This evidence concerns the gene NBN and ovarian cancer.